BioSpace News Archive

Addex Therapeutics Ltd announced today the initiation of a Phase 2a clinical study with dipraglurant as a potential treatment for blepharospasm, a type of dystonia characterized by involuntary contractions or spasms of the eyelid muscles

Biophytis SA announces it will present full results from the SARA-INT Phase 2 trial of Sarconeos in Sarcopenia at the International Congress on Frailty and Sarcopenia Research to be held virtually from September 29 to October 02, 2021.

XNK Therapeutics AB announced plans to further expand the scope of its proprietary technology platform of natural killer cell therapies outside of multiple myeloma to also include other cancer indications to broaden the pipeline.

Avacta Group plc is pleased to announce that a pre-clinical development milestone has been achieved in the multi-target therapeutics development partnership with LG Chem Life Sciences, the life sciences division of the South Korean LG Group, triggering an undisclosed milestone payment.

In last few years, there has been a notable rise in digital healthcare. It is based on an intersection of genomic & digital technology with healthcare and society.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per the insights by Fact.MR, the global dental lasers market is registered year on year growth at 9.0% in 2019.

Leveraging the industry expertise and capital of its new ownership group, Particle Dynamics, a global leader in particle processing with a fully integrated product portfolio, prepares for its next phase of growth in the global healthcare industry.

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the third quarter of 2021.

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will participate in a fireside chat at the Guggenheim 2nd Annual Vaccines & Infectious Day Conference.

TransMedics Group, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its OCS Liver System for use with organs from donors after brain death (DBD) and after circulatory death (DCD).